Free Trial

Centene (CNC) Stock Forecast & Price Target

$67.86
+0.61 (+0.91%)
(As of 07/12/2024 ET)

Centene - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$86.00
26.73% Upside
High Forecast$110.00
Average Forecast$86.00
Low Forecast$72.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Hold
Hold
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
9 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$86.00$84.93$85.38$86.28
Forecasted Upside26.73% Upside21.63% Upside21.11% Upside17.30% Upside
Get Centene Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.

CNC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Centene Stock vs. The Competition

TypeCenteneMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.71
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside26.73% Upside994.16% Upside9.20% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $83.00+23.16%
7/10/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$85.00 ➝ $80.00+21.56%
6/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$110.00 ➝ $110.00+64.08%
6/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00+32.28%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$83.00 ➝ $83.00+19.17%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$83.00+17.76%
5/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$101.00 ➝ $104.00+41.90%
4/30/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$81.00 ➝ $82.00+11.64%
4/15/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$89.00 ➝ $93.00+31.49%
12/21/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$83.00 ➝ $86.00+18.25%
12/21/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$72.00 ➝ $79.00+8.55%
9/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$79.00 ➝ $72.00+17.51%
8/30/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$94.00 ➝ $73.00+13.28%
7/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
7/11/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$80.00 ➝ $76.00+12.91%
4/26/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$94.00 ➝ $87.00+25.56%
2/14/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$101.00 ➝ $97.00+32.73%
2/8/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$97.00 ➝ $74.00+2.91%
2/8/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$110.00 ➝ $95.00+33.84%
12/14/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$95.00 ➝ $99.00+18.96%
9/22/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$108.00 ➝ $101.00+27.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:38 PM ET.

CNC Forecast - Frequently Asked Questions

What is Centene's forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Centene is $86.00, with a high forecast of $110.00 and a low forecast of $72.00.

Should I buy or sell Centene stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centene in the last twelve months. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CNC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNC, but not buy additional shares or sell existing shares.

Does Centene's stock price have much upside?

According to analysts, Centene's stock has a predicted upside of 24.62% based on their 12-month stock forecasts.

Has Centene been upgraded by Wall Street analysts recently?

Over the previous 90 days, Centene's stock had 1 upgrade by analysts.

What analysts cover Centene?
Do Wall Street analysts like Centene more than its competitors?

Analysts like Centene less than other "medical" companies. The consensus rating for Centene is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CNC compares to other companies.


This page (NYSE:CNC) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners